Three-year data from ongoing open-label study supported safety and effectiveness of seladelpar in patients with primary biliary cholangitis.

A pooled analysis of two phase 3 clinical trials shows that the first-in-class drug improves itching and itching-related ...

Sclerosing cholangitis and primary biliary cirrhosis, which is now called primary biliary cholangitis (PBC), are chronic cholestatic liver diseases, but they differ in their causes, affected bile ...

Primary biliary cholangitis (PBC) is a rare autoimmune disease affecting the bile ducts in the liver. When bile ducts become damaged, bile can build up in the liver, leading to inflammation and ...

Please provide your email address to receive an email when new articles are posted on . In a video exclusive, Marlyn Mayo, MD, of the University of Texas Southwestern Medical Center, reported ...

Initial data from ASSURE showed 70% of the 148 patients who completed 12 months of treatment with seladelpar achieved the composite response endpoint. Seladelpar was associated with improvement in ...

FDA on Wednesday restricted the use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) due to the risk of serious liver injury in patients with advanced cirrhosis. Serious side effects ...

Please provide your email address to receive an email when new articles are posted on . Primary biliary cholangitis (PBC) causes chronic inflammation and progressive destruction of the bile ducts, ...

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...

Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, and primary sclerosing cholangitis (PSC) both involve the breakdown of your bile ducts. Both conditions are also thought ...

PBC is a chronic liver disease that damages bile ducts and can lead to liver failure. You can get treatment for PBC to slow ...